Varying intervals of subcutaneous epoetin alfa in hemodialysis patients

Journal of Nephrology

Volumn 17, Issue 4, 2004, Pages 525-530

  Beshara, Soheir ^a   Bárány, Peter ^b   Guiterrez, Alberto ^b   Wikström, Björn ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anemia; C reactive protein; Dose interval; Hemodialysis; Iron deficiency; SC epoetin alfa

Indexed keywords

ALUMINUM; C REACTIVE PROTEIN; HEMOGLOBIN; IRON; PARATHYROID HORMONE; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ALUMINUM BLOOD LEVEL; ANEMIA; ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FREQUENCY ANALYSIS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; IRON DEFICIENCY; IRON STORAGE; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; SIDE EFFECT;

EID: 4644237484     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC, Evans RW, Friedman EA, Graber SE, Haley NR, Korbet S, Krantz SB, Lundin AP, Nissenson AR, Ogden DA, Paganini EP, Rader B, Rutsky EA, Stivelman J, Stone WJ, Teschan P, Van Stone JC, Van Wijk DB, Zuckerman K, Adamson JW. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann Intern Med 1989; 111: 992-1000.
2. Locatelli F, Baldamus C, Villa G, Ganea A, de Francisco AM. A rationale for an individualized administration frequency of epoetin β: a pharmacological perspective. Nephrol Dial Transplant 2002; 17 (suppl 6): S13-6.
3. Macdougall IC. Meeting the challenges of a new millennium: optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant 1998; 13: 23-7.
4. Piccoli A, Malagoli A, Komninos G, Pastori G. Subcutaneous epoetin-alfa every one, two, and three weeks in renal anemia. J Nephrol 2002; 15: 565-74.
5. Weiss L, Clyne N, Fihlho JD, Frisenette-Fich C, Kurkus J, Svensson B. The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin β: results from a randomized controlled multicentre trial. Nephrol Dial Transplant 2000; 15: 2014-9.
6. Ongkingco JR, Ruley EJ, Turner ME, Fragale MR. Efficacy of once-versus thrice-weekly subcutaneous recombinant human erythropoietin in children receiving continuous cycling peritoneal dialysis. Am J Nephrol 1994; 14: 14-8.
7. Lui SF, Law CB, Ting SM, Li P, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis. Clin Nephrol 1991; 36: 246-51.
8. Cheung WK, Goon BL, Guilfoyle MC, Walcholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 1998; 64: 412-23.
9. Macdougall IC. Once-weekly erythropoietic therapy: is there a difference between the available preparations? Nephrol Dial Transplant 2002; 17: 2047-51.
10. Beguin Y, Loo M, R'Zik S, Sautois B, Lejeune F, Rorive G, Fillet G. Quantitative assessment of erythropoiesis in haemodialysis patients demonstrates gradual expansion of eythroblasts during constant treatment with recombinant human erythropoietin. Br J Haematol 1995; 89: 17-23.
11. Gutmann FD, Schwartz JC. Pathogenesis of anemia secondary to chronic renal failure. In Garnick MB Ed. Erythropoietin in clinical practice. New York: Marcel Dekker 1990; 105-40.
12. Cooper AC, Mikhail A, Lethbridge MW, Kemny DM, Macdougall IC. Increased expression of erythropoiesis inhibiting cytokines (IFN-gamma, TNF-alfa, IL-10, and IL-13) by T cells in patients exhibiting a poor response to erythropoietin therapy. J Am Soc Nephrol 2003; 14: 1776-84.
13. Barany P, Divino Filho JC, Bergstrom J. High C-reactive protein is a strong predictor of resistance to erythropoietin in hemodialysis patients. Am J Kidney Dis 1997; 29: 565-8.
14. Danielson B. R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 1995; 10 (suppl 2): S69-73.
15. Locatelli F, Del Vecchio L. Pure red cell aplasia secondary to treatment with erythropoietin. J Nephrol 2003; 16: 461-6.